Diagnostic accuracy of general dermatologists and supportive oncodermatologists for biopsied cutaneous immune-related adverse events

[1]  N. LeBoeuf,et al.  Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. , 2022, JAMA dermatology.

[2]  J. McQuade,et al.  Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit , 2021, Cancer.

[3]  Omar Pacha,et al.  Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients , 2021, Supportive Care in Cancer.

[4]  Zhuoli Zhang,et al.  Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis , 2021, Frontiers in Oncology.

[5]  K. Reynolds,et al.  Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis. , 2021, Journal of the American Academy of Dermatology.

[6]  J. Said,et al.  Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. , 2021, JAMA dermatology.

[7]  J. Said,et al.  Effect of dermatological consultation on survival in patients with checkpoint inhibitor‐associated cutaneous toxicity , 2021, The British journal of dermatology.

[8]  J. Said,et al.  Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitors. , 2021, Journal of the American Academy of Dermatology.

[9]  C. Tan,et al.  Supportive oncodermatology—a narrative review of its utility and the way forward , 2021, Supportive Care in Cancer.

[10]  E. Nadelmann,et al.  Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer. , 2021, European journal of cancer.

[11]  N. LeBoeuf,et al.  Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center. , 2020, JAMA dermatology.

[12]  K. Reynolds,et al.  Dermatology Consultation Reduces Interruption of Oncologic Management Among Hospitalized Patients with Immune-related Adverse Events: A Retrospective Cohort Study. , 2020, Journal of the American Academy of Dermatology.

[13]  M. Marchetti,et al.  Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  R. Motzer,et al.  Treatment Outcomes of Immune-Related Cutaneous Adverse Events. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Sullivan,et al.  High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma , 2018, Cancer.

[16]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[17]  V. Sibaud.  Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.

[18]  J. Wargo,et al.  Diverse types of dermatologic toxicities from immune checkpoint blockade therapy , 2017, Journal of cutaneous pathology.

[19]  M. Rosenbach,et al.  Inpatient dermatology consultation in patients with hematologic malignancies. , 2016, Journal of the American Academy of Dermatology.

[20]  M. Lacouture,et al.  The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. , 2011, Journal of the American Academy of Dermatology.

[21]  W. Bergfeld,et al.  A retrospective biopsy study of the clinical diagnostic accuracy of common skin diseases by different specialties compared with dermatology. , 2005, Journal of the American Academy of Dermatology.